Physician profile
Deede Liu
NPI 1679791909
$1,524.96
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $929 · 2020: $274 · 2022: $321.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $385.73 | 2019-2020 | |
| Pfizer INC. | $329.89 | 2019-2022 | |
| Genzyme Corporation | $149.50 | 2022 | |
| Leo Pharma INC. | $86.12 | 2019-2020 | |
| Lilly USA, LLC | $79.06 | 2019-2020 | |
| Janssen Biotech, INC. | $74.39 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $71.35 | 2019-2020 | |
| Helsinn Therapeutics (U.S.), INC. | $61.17 | 2019 | |
| Sun Pharmaceutical Industries INC. | $59.02 | 2019-2020 | |
| Ucb, INC. | $39.07 | 2019 | |
| Celgene Corporation | $35.16 | 2019 | |
| Dermira, INC. | $34.37 | 2019 | |
| Genentech USA, INC. | $25.48 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $22.25 | 2019 | |
| Amgen INC. | $22.18 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $21.30 | 2020 | |
| Merck Sharp & Dohme LLC | $15.31 | 2020 | |
| Galderma Laboratories, L.P. | $13.61 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deede Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.